Login
$LYEL
$14.65 +$0.35 (2.45%) Live

$LYEL 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., November 4, 2026 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, to...

04 Nov 2026 8-K: Unregistered Sales of Equity Securities

On November 3, 2026, Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to...

10 Sep 2026 8-K: Other Events

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

06 Aug 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., August 6, 2026 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, toda...

15 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 10, 2026, Lyell Immunopharma, Inc. (the “Company”) virtually held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting via remote communication or by proxy were the holder...

06 May 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., May 6, 2026 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today r...

12 Mar 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., March 12, 2026 --Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today...

09 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

I am very pleased to confirm our offer to you of employment as Chief Financial and Business Officer at Lyell Immunopharma, Inc. (the “Company”). The opportunity to work with you to build one of the world’s great companies whose goal is n...

08 Dec 2025 8-K: Other Events

On December 7, 2025, Lyell Immunopharma, Inc. (the “Company”) presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition new clinical and translational data from its ongoing clinical trial of rondecabtagene ...

05 Dec 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Section 1. Registered Office. The registered office of Lyell Immunopharma, Inc. (the “Corporation”) in the State of Delaware and the name of its registered agent at such address shall be as set forth in the Amended and Restated Certifica...

12 Nov 2025 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., Nov.12 2025 --Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financi...

10 Nov 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

03 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

16 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

12 Aug 2025 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., August 12, 2025 --Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business ...

25 Jul 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 24, 2025, is made by and among LYELL IMMUNOPHARMA, INC., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their p...

26 Jun 2025 8-K: Unregistered Sales of Equity Securities

As previously reported, Lyell Immunopharma, Inc., a Delaware corporation (“Lyell” or the “Company”), completed its acquisition (the “Merger”) of ImmPACT Bio USA Inc., a Delaware corporation (“ImmPACT”), pursuant to the Agreement and Plan...

17 Jun 2025 8-K: Other Events

On June 17, 2025, Lyell Immunopharma, Inc. (the “Company”) announced new clinical data from its ongoing multi-center Phase 1/2 clinical trial of LYL314, including data from patients with large B-cell lymphoma (“LBCL”) treated in the thir...

09 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 May 2025 8-K: Material Modification to Rights of Security Holders

Lyell Immunopharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support